Type-2 alkenes mediate synaptotoxicity in neurodegenerative diseases
Related Experiment Video
Updated: Jul 4, 2026

A High-content Assay for Monitoring AMPA Receptor Trafficking
Published on: January 28, 2019
Richard M Lopachin1, Terrence Gavin, David S Barber
1Department of Anesthesiology, Albert Einstein College of Medicine, Montefiore Medical Center, Moses Research Tower 7, 111 East 2210th Street, Bronx, NY 10467-2490, United States. lopachin@aecom.yu.edu
Abstract:
Synaptic dysfunction appears to be an early pathogenic event in Alzheimer's disease, amyotrophic lateral sclerosis and Parkinson's disease. Although the molecular mechanism of this synaptotoxicity is not known, evidence suggests that these diseases are characterized by a common pathophysiological cascade involving oxidative stress, lipid peroxidation and the subsequent liberation of alpha,beta-unsaturated carbonyl derivatives such as acrolein and 4-hydroxy-2-nonenal (HNE). A diverse body of in vivo and in vitro data have shown that these soft electrophilic chemicals can cause nerve terminal damage by forming Michael-type adducts with nucleophilic sulfhydryl groups on presynaptic proteins. Therefore, the endogenous generation of acrolein and HNE in oxidatively stressed neurons of certain brain regions might be mechanistically related to the synaptotoxicity associated with neurodegenerative conditions. In addition, acrolein and HNE are members of a large class of structurally related chemicals known as the type-2 alkenes. Chemicals in this class (e.g., acrylamide, methylvinyl ketone, and methyl acrylate) are pervasive pollutants in human environments and new research has shown that these alpha,beta-unsaturated carbonyl derivatives are also toxic to nerve terminals. In this review, we provide evidence that the regional synaptotoxicity, which develops during the early stages of many neurodegenerative diseases, is mediated by endogenous generation of acrolein and HNE. Based on a presumed common nerve terminal site of action, we propose that the onset and progression of this neuropathogenic process is accelerated by environmental exposure to other type-2 alkenes.
Insights
Oxidative stress in neurodegenerative diseases generates toxic compounds like acrolein and 4-hydroxy-2-nonenal (HNE), causing nerve damage. Environmental exposure to similar chemicals may accelerate disease progression.
Area of Science:
- Neuroscience
- Toxicology
- Biochemistry
Background:
- Synaptic dysfunction is an early hallmark of Alzheimer's, Parkinson's, and ALS.
- A common pathway involving oxidative stress, lipid peroxidation, and alpha,beta-unsaturated carbonyls (acrolein, HNE) is implicated.
Purpose of the Study:
- To review evidence linking endogenous acrolein and HNE to neurodegenerative synaptotoxicity.
- To propose a common mechanism of nerve terminal damage mediated by these compounds.
- To explore the role of environmental type-2 alkenes in accelerating neuropathogenesis.
Main Methods:
- Review of in vivo and in vitro studies on neurodegenerative diseases.
- Analysis of biochemical pathways involving oxidative stress and lipid peroxidation.
- Examination of the toxicological effects of alpha,beta-unsaturated carbonyls on neurons.
Main Results:
- Endogenous acrolein and HNE formation correlates with neuronal oxidative stress.
- These compounds form adducts with presynaptic proteins, leading to nerve terminal damage.
- Environmental type-2 alkenes share similar mechanisms of synaptotoxicity.
Conclusions:
- Endogenous acrolein and HNE are key mediators of regional synaptotoxicity in early neurodegenerative diseases.
- A common mechanism of nerve terminal damage is proposed for these conditions.
- Environmental exposure to type-2 alkenes may exacerbate neurodegeneration.
Related Concept Videos
Alzheimer Disease ll: Pathophysiology
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Drugs Affecting Neurotransmitter Synthesis
Parkinson Disease ll: Pathophysiology
Alzheimer's Disease: Treatment
Alzheimer Disease l: Introduction
